HMN 2025: How Successful CAR-T cell remedy for end-stage a number of myeloma utilizing superior mobile product is carried out in Hong Kong

A medical staff has spearheaded using CAR-T cell remedy for blood cancers. The researchers not too long ago handled the primary myeloma affected person with this remedy, leading to an excellent response with out extreme problems. The growth of this modern therapy to myeloma sufferers presents new hope for many who haven’t responded to conventional therapy, marking a major milestone in advancing well being care in Hong Kong.

Importantly, the therapy for these sufferers represents the primary time superior CAR-T mobile remedy manufactured within the mainland has been utilized in Hong Kong, opening new prospects for using novel superior mobile therapies from the mainland in Hong Kong and probably benefiting a broader vary of sufferers sooner or later.

Myeloma is a cancerous dysfunction of plasma cells that happens primarily in sufferers of their forties and fifties, although youthful sufferers are additionally in danger. The illness causes anemia, bone destruction and kidney harm, in the end leading to loss of life.

The present commonplace of look after myeloma entails using frontline goal brokers, sometimes together with chemotherapy, adopted by autologous hematopoietic stem cell transplantation. However, many sufferers nonetheless expertise a illness relapse. For those that relapse or fail to reply to frontline therapy, choices are restricted, with solely short-lived advantages from bispecific antibodies and different focused medicine. For sufferers who relapse and don’t reply to conventional therapies, the illness typically turns into terminal.

CAR-T cells remedy is an modern strategy to assist sufferers battle cancers with their very own immune system. CAR-T cells are genetically engineered T-lymphocytes that specific a chimeric antigen receptor focusing on a selected antigen on cancer cells. In commonplace CAR-T cell remedy, these T-lymphocytes are derived from the affected person (therefore, autologous) and are actually accessible for treating blood cancers, together with leukemia, lymphomas and myeloma.

Queen Mary Hospital was the primary hospital in Hong Kong to supply CAR-T cell remedy in 2021. The medical staff has efficiently carried out CAR-T remedy on over 60 sufferers with numerous blood cancers, representing the most important cohort of CAR-T cell-treated sufferers in Hong Kong.

Research strategies and findings

The therapy course of begins with gathering T-lymphocytes from the affected person’s peripheral blood, a course of often known as apheresis. These T-lymphocytes are then transported to a producing website, where the CAR assemble is inserted. While the genetically modified CAR-T cells are returned to the therapy website, the affected person undergoes chemotherapy to clear circulating lymphocytes, a course of often known as lymphodepletion. Following the completion of lymphodepletion, the CAR-T cells are re-infused again to the affected person.

The CAR-T cells used for myeloma goal an antigen known as B-cell maturation antigen (BCMA). The analysis staff makes use of BCMA CAR-T cells produced from a producer within the mainland. This product has been in use since 2020 and acquired approval from the National Medical Products Administration in 2023. This is the primary time this product has been used outdoors the mainland.

Significance of the therapy

“Currently, Queen Mary Hospital is the one hospital in Hong Kong providing CAR-T cell immunotherapy for myeloma. The present pilot CAR-T cell remedy program goals to deal with 5 to 10 myeloma sufferers yearly,” mentioned Professor Kwong Yok-lam, Chair Professor of the Department of Medicine, School of Clinical Medicine, HKUMed.

Professor Eric Tse Wai-choi, Associate Dean (Research) of the Faculty and Clinical Professor in the identical Department, added, “BCMA CAR-T cell remedy could have a major influence on myeloma administration in Hong Kong, because it represents one of the vital efficient salvage methods for myeloma. It can present a life-saving choice for sufferers who don’t reply to straightforward remedy or expertise a relapse after autologous bone marrow transplantation.”

The use of BCMA CAR-T cell remedy in these sufferers marks the primary utility of superior medical know-how from the mainland in Hong Kong. It exemplifies how state-of-the-art therapeutic merchandise and know-how developed within the mainland can profit sufferers in Hong Kong and paves the best way for accessing extra modern therapy methods from the mainland to be used in Hong Kong.